(AGENPARL) – Tue 25 March 2025 Lund, Sweden, 25 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm:
HNSA) today announced it will attend Van Lanschot Kempen Life Sciences
Conference in Amsterdam, NL, on 2-3 April. Hansa management will be available
for meetings at the conference. If you are interested in meeting with the
To learn more about Hansa Biopharma see the latest Corporate
Presentation here. (https://www.hansabiopharma.com/investors/presentations
-events/) The Company’s year-end financial report can be
found here (https://www.hansabiopharma.com/investors/financial-reports/).
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on
a mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. The company has a
rich and expanding research and development program based on its proprietary IgG
-cleaving enzyme technology platform, to address serious unmet medical needs in
autoimmune diseases, gene therapy and transplantation. The company’s portfolio
includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving
enzyme therapy, which has been shown to enable kidney transplantation in highly
sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with
redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations
in Europe and the U.S. The company is listed on Nasdaq Stockholm under the
ticker HNSA. Find out more at http://www.hansabiopharma.com and follow us on
LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3aGrY9BBNaxcNBtNHJ8UJenXp6eebRePUazQCDAdXtYV6WsE8xCyEyPGMLQs3tbziNaGfdCktw9Yt1GPpRgKDvumAD8WAwZ8ZYSK2rvGBQKUro.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3aGrY9BBNaxcNBtNHJ8UJenXp6eebRePUazQCDAdXtYV6WsE8xCyEyPGMLQs3tbziNaGfdCktw9Yt1GPpRgKDvumAD8WAwZ8ZYSK2rvGBQKUro.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content